Détail de la revue
Documents disponibles dans cette revue
trié(s) par (Pertinence décroissant(e), Date de parution décroissant(e), Date de parution décroissant(e), Système de projection du document croissant(e)) Mettre toutes les notices dans le panier Faire une suggestion Ajouter un critère de recherche
From diagnosis to prognosis: Revisiting the meaning of muscle ISG15 overexpression in juvenile inflammatory myopathies
Hou C, Durrleman C, Periou B, et al.
Arthritis & rheumatology (Hoboken, N.J.), 2020
Study of Tofacitinib In Refractory Dermatomyositis (STIR): An open label pilot study of 10 patients
Paik JJ, Casciola-Rosen L, Shin JY, et al.
Arthritis & rheumatology (Hoboken, N.J.), 2020
Risk prediction modeling based on a combination of initial serum biomarkers in myositis-associated interstitial lung disease
Gono T, Masui K, Nishina N, et al.
Arthritis & rheumatology (Hoboken, N.J.), 2020
Endothelial and inflammatory biomarker profile at diagnosis reflects clinical heterogeneity of juvenile dermatomyositis and is prognostic for response to treatment in two independent cohorts
Wienke J, Pachman LM, Morgan GA, et al.
Arthritis & rheumatology (Hoboken, N.J.), 2020
Muscle weakness in myositis: microRNAs mediate dystrophin reduction in MHC class I transgenic mouse model and human muscle biopsies
Kinder TB, Heier CR, Tully CB, et al.
Arthritis & rheumatology (Hoboken, N.J.), 2020
Circulating interferon-alpha measured with a highly sensitive assay as a biomarker for juvenile inflammatory myositis activity
Melki I, Devilliers H, Gitiaux C, et al.
Arthritis & rheumatology (Hoboken, N.J.), 2020, 72, 1, p 195
A Multicenter Prospective Study of the Efficacy and Safety of Combined Immunosuppressive Therapy with High-Dose Glucocorticoid, Tacrolimus, and Cyclophosphamide in Interstitial Lung Diseases Accompanied by Anti-Melanoma Differentiation-Associated Gene 5-Positive Dermatomyositis
Tsuji H, Nakashima R, Hosono Y, et al.
Arthritis & rheumatology (Hoboken, N.J.), 2019
Neutrophil Extracellular Traps in Tissue and Periphery in Juvenile Dermatomyositis
Duvvuri B, Pachman LM, Morgan G, et al.
Arthritis & rheumatology (Hoboken, N.J.), 2019
The IgG2 isotype of anti-transcription intermediary factor 1-gamma autoantibodies is a biomarker of mortality in adult dermatomyositis
Aussy A, Fréret M, Gallay L, et al.
Arthritis & rheumatology (Hoboken, N.J.), 2019
Galectin-9 and CXCL10 as biomarkers for disease activity in juvenile dermatomyositis: a longitudinal cohort study and multi-cohort validation
Wienke J, Bellutti Enders F, Lim J, et al.
Arthritis & rheumatology (Hoboken, N.J.), 2019
Efficacy and safety of cyclophosphamide treatment in severe juvenile dermatomyositis shown by marginal structural modelling
Deakin CT, Campanilho-Marques R, Simou S, et al.
Arthritis & rheumatology (Hoboken, N.J.), 2018
2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Adult Dermatomyositis and Polymyositis : An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative
Aggarwal R, Rider LG, Ruperto N, et al.
Arthritis & rheumatology (Hoboken, N.J.), 2017, 69, 5, p 898
2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis : An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative
Rider LG, Aggarwal R, Pistorio A, et al.
Arthritis & rheumatology (Hoboken, N.J.), 2017, 69, 5, p 911
Immune-array Analysis in Sporadic Inclusion Body Myositis Reveals HLA-DRB1 Amino Acid Heterogeneity across the Myositis Spectrum
Rothwell S, Cooper RG, Lundberg IE, et al.
Arthritis & rheumatology (Hoboken, N.J.), 2017, 69, 5, p 1090
2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis
Buckley L, Guyatt G, Fink HA, et al.
Arthritis & rheumatology (Hoboken, N.J.), 2017, 69, 8, p 1521
Myositis autoantibodies, clinical features, and environmental exposures at illness onset are associated with disease course in juvenile myositis
Habers GE, Huber AM, Mamyrova G, et al.
Arthritis & rheumatology (Hoboken, N.J.), 2016, 68, 3, p 761
Interferon-alpha inhibition by intravenous immunoglobulin is independent of modulation of the plasmacytoid dendritic cell population in the circulation: comment on the article by Wiedeman et al
Sharma M, Saha C, Schoindre Y, et al.
Arthritis & rheumatology (Hoboken, N.J.), 2014, 66, 8, p 2308
A26: longitudinal disease trajectory of juvenile dermatomyositis : Actes de colloque - Poster Presentations from the 2014 Pediatric Rheumatology Symposium
Hoon Lim LS, Pullenayegum E, Gladman DD, et al.
Arthritis & rheumatology (Hoboken, N.J.), 2014, 66, S3, p S41
A47: Progress Report on the development of new classification criteria for adult and juvenile idiopathic inflammatory myopathies : Actes de colloque - Poster Presentations from the 2014 Pediatric Rheumatology Symposium
Pilkington C, Tjärnlund A, Bottai M, et al.
Arthritis & rheumatology (Hoboken, N.J.), 2014, 66, S3, p S70
A58: Demographics, clinical features and therapies of patients with juvenile dermatomyositis participating in a national myositis patient registry : Actes de colloque - Poster Presentations from the 2014 Pediatric Rheumatology Symposium
Rider LG, Faiq A, Farhadi PN, et al.
Arthritis & rheumatology (Hoboken, N.J.), 2014, 66, S3, p S86
